


## Spotlight on Research Fees: Cost per Subject in Asia Pacific

By Rafael A Campo

From 2006-2008 to 2009-2011, mean cost per subject in Phase II and III clinical trials decreased by 14% in Asia Pacific.<sup>1</sup> In contrast, per subject costs in the United States rose by 23% over the same time period. China has seen the largest increase: 32%. Over half the selected countries have seen a decrease. Malaysia has seen the sharpest decrease in cost per subject, 33%, and is now the lowest-priced country in the region. Hong Kong, Australia, Singapore and India have shown modest decreases: 15%, 14%, 13% and 11%, respectively.

### Cost per Subject in Asia Pacific

(Mean, Selected Asia Pacific Countries, Phases II & III, All Therapeutic Areas, Industry-Sponsored Pharmaceutical and Biotechnology Studies, 2006-2011)<sup>1</sup>



### Notes & References

1. Source: Medidata Grants Manager™, the PICAS® database

### Author

Rafael A Campo is the Manager of Data Quality and Analytics at Medidata Solutions, Inc. Contact him at 1.215.358.1429 or rcampo@mdsol.com.